Suchergebnisse - "Haidar, Ghady"

PubPharm (102)

51

Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2021

von Haidar, G. | Mellors, J.

CommentIn: Clin Infect Dis. 2022 Feb 11;74(3):553. - PMID 34157075

52

A Learning Health System Randomized Trial of Monoclonal Antibodies for Covid-19

enthalten in: bioRxiv.org | 2021

von McCreary, E. | Bariola, J. | Minnier, T. | +35

53

Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania

enthalten in: Journal of clinical virology plus | 2021

von Rapsinski, G. | Freeman, M. | Haidar, G. | +3

54

Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient : A Case Study

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2021

von Hensley, M. | Bain, W. | Jacobs, J. | +30

55

Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

enthalten in: Open forum infectious diseases | 2021

von Bariola, J. | McCreary, E. | Wadas, R. | +19

56

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies : A Need for Vigilance in the Postmasking Era

enthalten in: Open forum infectious diseases | 2021

von Agha, M. | Blake, M. | Chilleo, C. | +2

UpdateOf: medRxiv. 2021 Apr 07;:. - PMID 33851182

57

The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial : a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization

enthalten in: Trials | 2021

von Huang, D. | McCreary, E. | Bariola, J. | +29

58

The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization

enthalten in: Trials | 2021

von Huang, D. | McCreary, E. | Bariola, J. | +29

59

In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam

enthalten in: Antimicrobial agents and chemotherapy | 2021

von Rubio, A. | Kline, E. | Jones, C. | +8

60

Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients

enthalten in: medRxiv : the preprint server for health sciences | 2021

von Agha, M. | Blake, M. | Chilleo, C. | +2

UpdateIn: Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353. - PMID 34337100